financially supported by the National Key R&D Program of China (2019YFC1605003);the Zhejiang Provincial Natural Science Foundation of China (LGN21C200013)。
Bacillus coagulans has been extensively studied so far,but there has been a lack of research on its usage in allergy.In this study,we designed to assess the effect of different concentrations of B.coagulans on food al...
The commented study reports the results of monotherapy using TQ-B3525,a novel phosphatidylinositol-3 kinase(PI3K)inhibitor developed in China,in patients with refractory/relapsed follicular lymphoma(r/r FL).
This study was sponsored by Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.(Nanjing,China)and was supported by grants from National Natural Science Foundation of China(Grant Number,81872902,82073917,and 82070206);National Natural Science Foundation of Guangdong Province(Grant Number,2023A1515011525);The Lymphoma Research Fund of China Anti-Cancer Association,and the Sun Yat-sen University Cancer Center Clinical Research 308 Program(Grant Number,2014-fxy-106 and 2016-fxy-079);Tianjin Key Medical Discipline(Specialty)Construction Project(Grant Number,TJYXZDXK-053B).
This registration study assessed clinical outcomes of TQ-B3525,the dual phosphatidylinositol-3-kinase(PI3K)α/δinhibitor,in relapsed and/or refractory follicular lymphoma(R/R FL).This phase II study(ClinicalTrials.go...